VALIRX PLC

Management Reports • Oct 11, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2470T

ValiRx PLC

11 October 2017

VALIRX PLC

("ValiRx", the "Company" or the "Group")

NOTIFICATION OF US PATENT ALLOWANCE

FOR THERAPEUTIC COMPOUND, VAL401

London, UK., 11 October 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to report that ValiSeek Limited ("ValiSeek"), the joint venture between ValiRx and Tangent Reprofiling Limited ("Tangent"), announces a new US patent allowance and an update on its patent portfolio.  The clinical stage therapeutic compound VAL401 has recently completed dosing in Phase II clinical trials to treat patients with lung cancer.  ValiSeek was formed to progress VAL401 into Clinical trials for the treatment of lung cancer and other oncology indications.

Notification of a Fifth US Patent Allowance for VAL401

ValiSeek has received notification that a further method-of-treatment patent has been allowed by the US Patent Office covering the use of VAL401 in the treatment of prostate adenocarcinoma.  The table below provides details of patents in the VAL401 portfolio that have been either fully granted or allowed.  International patents are pending across Europe, Asia, Australasia and in North and South America, providing coverage in all significant markets worldwide.

Dr Suzy Dilly, CEO of ValiSeek, commented: "It is really pleasing to receive this notification of allowance for this latest VAL401 patent so close on the heels after our encouraging and positive announcement of first verified clinical data emerging from the VAL401 trial in Tbilisi, Georgia.  This allowance will further strengthen ValiSeek's portfolio at an important time in our development pathway and will grow the confidence of existing and potential partners, as far as bringing this compound closer to the marketplace".

Country	Patent number	Date Filed	Date Granted/Allowed
United States	US 9072743	26 September 2013	07 July 2015
United States	US 9375433	08 May 2015	28 June 2016
United States	US 9585887	27 May 2015	07 March 2017
United States	US 9585890	31 May 2016	07 March 2017
United States	To be allocated shortly	27 February 2017	Allowed
Australia	AU 2013322612	26 September 2013	14 September 2017
New Zealand	NZ 706067	26 September 2013	01 November 2016

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Richard Nash	Tel: +44 (0) 20 7213 0880
Beaufort Securities Limited (Broker) Jon Belliss	Tel: +44 (0) 207 382 8300

Notes for Editors

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESQBLFFDBFXFBD